To predict prostate cancer by ultrasound radiomics in ultrasound fusion prostate targeted biopsy.

Researchers plan to develop a diagnostic and prognostic evaluation model for prostate cancer by analyzing abnormal echoes in prostate ultrasound images through radiomics. This model will be used to guide ultrasound radiomics-fusion prostate biopsy, and its accuracy will be compared with that of systematic biopsy.

Inclusion Criteria:

1. Age ≥55 years old.

2. Patients had tPSA/fPSA within 1 month before biopsy.

3. Patients had any of the following indications for prostate biopsy:

   • Suspicious prostate nodules were found by digital rectal examination
   • Suspicious lesions were detected by B-ultrasound or MRI
   • PSA>10ng/ml
   • PSA 4-10ng/ml, with abnormal f/tPSA and/or PSAD values

Exclusion Criteria:

1. malignant tumors other than prostate adenocarcinoma indicated by pathology.
2. Combined with other malignant tumors (such as rectal cancer, bladder cancer, testicular cancer, etc.) that may affect the imaging findings of transrectal ultrasound or mpMRI.
3. Other conditions that would preclude needle biopsy: cachexia, decompensation of organ function, hemorrhagic diseases, local infection, etc

Patients aged above 55 who had an indication for prostate biopsy will be screened for eligibility.